Drug Information

Drug (ID: DG01885) and It's Reported Resistant Information

• Name: UNC1999
• Synonyms: UNC1999
• Indication:
  In total 1 Indication(s)
  Discovery agent [ICD-11: N.A.]; Approved; [1]
• Target: Enhancer of zeste homolog 2 (EZH2); EZH2_HUMAN; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Diffuse large B-cell lymphoma [ICD-11: 2A81]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Histone-lysine N-methyltransferase EZH2 (EZH2) [1]

• Molecule Alteration: Missense mutation; p.Y641N (c.1921T>A)
• Sensitive Disease: Diffuse large B-cell lymphoma [ICD-11: 2A81.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: MCF10A cells; Breast; Homo sapiens (Human); CVCL_0598
• Mechanism Description: The missense mutation p.Y641N (c.1921T>A) in gene EZH2 cause the sensitivity of UNC1999 by aberration of the drug's therapeutic target

References

• Ref 1: An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1ACS Chem Biol. 2013;8(6):1324-34. doi: 10.1021/cb400133j. Epub 2013 Apr 24.